Literature DB >> 28501254

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis.

Bradley Hall1, James Padussis2, Jason M Foster3.   

Abstract

Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CC score; Cytoreductive surgery (CRS); Hyperthermic intraperitoneal chemotherapy (HIPEC); Intraperitoneal chemotherapy (IP); Peritoneal carcinoma index (PCI); Peritoneal metastasis (PM); R score

Mesh:

Substances:

Year:  2017        PMID: 28501254     DOI: 10.1016/j.suc.2017.01.013

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  6 in total

Review 1.  Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges.

Authors:  Onno Kranenburg; Kurt van der Speeten; Ignace de Hingh
Journal:  Front Oncol       Date:  2021-03-16       Impact factor: 6.244

2.  In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany.

Authors:  Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath
Journal:  Ann Surg Oncol       Date:  2020-11-09       Impact factor: 5.344

3.  Severe pulmonary complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are common and contribute to decreased overall survival.

Authors:  Olivia Sand; Mikael Andersson; Erebouni Arakelian; Peter Cashin; Egidijus Semenas; Wilhelm Graf
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

4.  Clinical Value of PET.CT Based on Big Data in Colorectal and Peritoneal Metastatic Cancer.

Authors:  Lili Xiang; Chuanhua Yang; Wenneng Liu; Dong Li; Zongze Jiang; Huijun Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-09-30       Impact factor: 3.009

5.  Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors.

Authors:  Philipp Horvath; Can Yurttas; Stefan Beckert; Alfred Königsrainer; Ingmar Königsrainer
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

6.  Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.

Authors:  Jason M Foster; Richard Sleightholm; Asish Patel; Valerie Shostrom; Bradley Hall; Beth Neilsen; David Bartlett; Lynette Smith
Journal:  JAMA Netw Open       Date:  2019-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.